Nuria Fabri-Faja

Nuria Fabri-Faja

Auto-generated profile, based on publicly available information

Nuria Fabri-Faja

Nanobiosensors and Bioanalytical Applications Group, Catalan Institute of Nanoscience and Nanotechnology (ICN2), CSIC, CIBER-BBN and BIST, Campus UAB, 08193, Bellaterra (Barcelona), Spain

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2019 in Analytica Chimica Acta
Verified
Journal Article
Open access
NFNuria Fabri-Faja
Nuria Fabri-Faja
OCOlalla Calvo-Lozano
Olalla Calvo-Lozano
Priyanka DeyPriyanka Dey
Priyanka Dey
RTRoland A. Terborg
Roland A. Terborg
M.-Carmen EstevezM.-Carmen Estevez
M.-Carmen Estevez
LLLaura M. Lechuga
Laura M. Lechuga
Sepsis is a condition characterized by a severe stage of blood-infection often leading to tissue damage, organ failure and finally death. Fast diagnosis and identification of the sepsis stage (sepsis, severe sepsis or septic shock) is critical for the patient's evolution and could help in defining the most adequate treatment in order to reduce its mortality. The combined detection of several biomarkers in a timely, specific and simultaneous way could ensure a more accurate diagnosis. We have designed a new optical point-of-care (POC) device based on a phase-sensitive interferometric biosensor with a label-free microarray configuration for potential high-throughput evaluation of specific sepsis biomarkers. The sensor chip, which relies on the use of metallic nanostructures, provides versatility in terms of biofunctionalization, allowing the efficient immobilization of different kind of receptors such as antibodies or oligonucleotides. We have focused on two structurally different types of biomarkers: proteins, including C-reactive protein (CRP) and Interleukin 6 (IL6), and miRNAs, using miRNA-16 as an example. Limits of Detection (LoD) of 18 μg mL-1, 88 μg mL-1 and 1 μM (6 μg mL-1) have been respectively obtained for CRP, IL6 and miRNA-16 in individual assays, with high accuracy and reproducibility. The multiplexing capabilities have also been assessed with the simultaneous analysis of both protein biomarkers.

7 December 2018 in ACS Sensors
Verified
Journal Article
Open access
Priyanka DeyPriyanka Dey
Priyanka Dey
NFNuria Fabri-Faja
Nuria Fabri-Faja
OCOlalla Calvo-Lozano
Olalla Calvo-Lozano
RTRoland A. Terborg
Roland A. Terborg
ABAlexander Belushkin
Alexander Belushkin
Laura M. LechugaLaura M. Lechuga
Laura M. Lechuga
Existing clinical methods for bacteria detection lack in speed, sensitivity and importantly in Point-of-Care (PoC) applicability. Thus, finding ways to push the sensitivity of clinical PoC biosensing technologies is crucial. Aiming that, we here report a portable PoC device based on Lens-free Interferometric Microscopy (LIM). The device employs high performance nanoplasmonics and custom bioprinted microarrays and is capable of direct label-free bacteria (E. coli) quantification. With only one-step sample handling we offer a sampletodata turnaround time of 40 minutes. Our technology features detection sensitivity of a single bacterial cell both in buffer and diluted blood plasma and is intrinsically limited by the number of cells present in the detection volume. When employed in a hospital setting, the device has enabled accurate categorization of sepsis patients (infectious SIRS) from control groups (healthy individuals and non-infectious SIRS patients) without false positives/negatives. User-friendly on-site bacterial clinical diagnosis can thus become a reality.